Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.32 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.31 |
| ▸ | CTRC | Q99895 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4643410 | 0.81 | CYP2A6 (0.34) | CYP2A6 | |
| SCHEMBL4647070 | 0.80 | CYP2A6 (0.33) | CYP2A6 | |
| SCHEMBL4644478 | 0.75 | HDAC3 (0.32) | — | |
| SCHEMBL6002962 | 0.70 | CYP1A2 (0.38) | CYP2A6 | |
| SCHEMBL5429261 | 0.70 | — | — | |
| SCHEMBL4646820 | 0.70 | CYP2A6 (0.30) | CYP2A6 | |
| SCHEMBL4644784 | 0.69 | CYP2A6 (0.52) | CYP2A6 | |
| SCHEMBL2094902 | 0.67 | CYP2A6 (0.44) | CYP2A6 | |
| SCHEMBL13184247 | 0.65 | DYRK1A (0.41) | CTRC | |
| SCHEMBL17306539 | 0.64 | DAO (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1298130-B1 | 3-HYDROXYMETHYLBENZO B THIOPHENE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | TEIJIN PHARMA LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-6774245-B2 | SELECTIVE HYDROGENATION OF 7-SUBSTITUTED-3-HYDROXYMETHYL-BENZO(B)THIOPHENE DERIVATIVE; CYCLIZATION, SULFIDING | TEIJIN LIMITED (JP) | 2004-08-10 | — | — | US | disclosed |
| US-20030191325-A1 | 3-Hydroxymethylbenzo[b]thiophene derivatives and process for their preparation | TEIJIN LIMITED (JP) | 2003-10-09 | — | — | US | disclosed |
| EP-1298130-A1 | 3-HYDROXYMETHYLBENZO B THIOPHENE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | TEIJIN LIMITED (JP) | 2003-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191325-A1 | 3-Hydroxymethylbenzo[b]thiophene derivatives and process for their preparation | TST, SULT1E1, CYP4B1 | CYP2A6 163/4885PSEN1 4610/4885PSEN2 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.